Aki Sako

Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid

T. Iwaki, K. Iihara, M. Mizoguchi, 2021, Journal of Neuro-Oncology.

Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma

T. Yoshiura, A. Hiwatashi, O. Togao, 2021, Journal of Neuro-Oncology.

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma

A. Hiwatashi, O. Togao, T. Iwaki, 2021, Cancer medicine.

Liquid biopsy with multiplex ligation-dependent probe amplification targeting cell-free tumor DNA in cerebrospinal fluid from patients with adult diffuse glioma

M. Mizoguchi, A. Nakamizo, Hidetaka Yamamoto, 2022, Neuro-oncology advances.

Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study

A. Hiwatashi, O. Togao, T. Iwaki, 2021, World Neurosurgery.

In-house molecular diagnosis of diffuse glioma updating the revised WHO classification by a platform of the advanced medical care system, Senshin-Iryo.

M. Mizoguchi, Yuhei Sangatsuda, T. Amemiya, 2024, Neuropathology : official journal of the Japanese Society of Neuropathology.

Hemizygous deletion of cyclin-dependent kinase inhibitor 2A/B with p16 immuno-negative and methylthioadenosine phosphorylase retention predicts poor prognosis in IDH-mutant adult glioma

M. Mizoguchi, Yuhei Sangatsuda, N. Hata, 2024, Neuro-oncology advances.